Previous close | 14.66 |
Open | 13.25 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 135.00 |
Expiry date | 2024-01-19 |
Day's range | 13.25 - 14.66 |
Contract range | N/A |
Volume | |
Open interest | N/A |
AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.*
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).